Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab

被引：32

作者：

Turgeman, Ilit ^{[1
,2
]}

Wollner, Mira ^{[1
,2
]}

Hassoun, Gamal ^{[1
,3
]}

Bonstein, Lilach ^{[1
,4
]}

Bar-Sela, Gil ^{[1
,2
,5
]}

机构：

[1] Technion Israel Inst Technol, Rambam Hlth Care Campus, Haifa, Israel

[2] Technion Israel Inst Technol, Dept Oncol, Haifa, Israel

[3] Technion Israel Inst Technol, Dept Immunol, Haifa, Israel

[4] Technion Israel Inst Technol, Platelet & Neutrophil Immunol Labs, Haifa, Israel

[5] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel

来源：

ANTI-CANCER DRUGS | 2017年 / 28卷 / 07期

关键词：

autoimmune; checkpoint inhibitor; hematological toxicity; immune-related adverse event; immunotherapy; lung cancer; neutropenia; nivolumab;

D O I：

10.1097/CAD.0000000000000520

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Checkpoint inhibitors effectively enhance the natural immune response against cancer, but they are also known to induce a unique spectrum of immune-related adverse events. Here, we report the first case of isolated neutropenia subsequent to nivolumab therapy. Prominent activated T-cells were found in the patient's serum and bone marrow alongside evidence of maturational defects in neutrophil precursors. Antineutrophil antibodies were not detected despite reliable testing techniques. A T-cell-mediated response is probable, consistent with the established mechanism for the development of other immune-related toxicities. Awareness of this rare and severe side effect reinforces the importance of early diagnosis and prompt initiation of proper treatment.

引用

页码：811 / 814

页数：4

共 11 条

[1]

Pennock G., Chow L., The evolving role of immune checkpoint inhibitors in cancer treatment, Oncologist, 20, pp. 812-822, (2015)

[2]

Michot J.M., Bigenwald C., Champiat S., Collins M., Carbonnel F., Postel-Vinay S., Et al., Immune-related adverse events with immune checkpoint blockade: A comprehensive review, Eur J Cancer, 54, pp. 139-148, (2016)

[3]

Akhtari M., Curtis B., Waller E., Autoimmune neutropenia in adults, Autoimmun Rev, 9, pp. 62-66, (2009)

[4]

Wlodarski M.W., Nearman Z., Jiang Y., Lichtin A., Maciejewski J.P., Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia, Exp Hematol, 36, pp. 293-300, (2008)

[5]

Naidoo J., Page D.B., Li B.T., Connell L.C., Schindler K., Lacouture M.E., Et al., Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, 26, pp. 2375-2391, (2015)

[6]

McNab F.W., Berry M.P., Graham C.M., Bloch S.A., Oni T., Wilkinson K.A., Et al., Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis, Eur J Immunol, 41, pp. 1941-1947, (2011)

[7]

Good-Jacobson K., Szumilas C., Chen L., Sharpe A., Tomayko M., Shlomchik M., PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells, Nature Immunol, 11, pp. 535-542, (2010)

[8]

Younes A., Santoro A., Shipp M., Zinzani P.L., Timmerman J.M., Ansell S., Et al., Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-Arm phase 2 trial, Lancet Oncol, 17, pp. 1283-1294, (2016)

[9]

Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, pp. 23-34, (2015)

[10]

Akhtari M., Waller E.K., Jaye D.L., Lawson D.H., Ibrahim R., Papadopoulos N.E., Arellano M.L., Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody, J Immunother, 32, pp. 322-324, (2009)

← 1 2 →